Zai Lab (HKG:9688) incurred $101.8 million in net loss in the first half of the year, wider by 14% from $89.2 million a year earlier, according to a Wednesday filing to the Hong Kong stock exchange.
Loss per share came in at $0.09 compared with $0.08 a year earlier, the biopharmaceutical company said.
Net product revenue during the period fell 6% to $201.3 million from $214.7 million a year prior.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.